{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:26:03Z","timestamp":1789118763211,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404767"],"award-info":[{"award-number":["82404767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Medical Insurance Bureau","award":["IIT-2025-63"],"award-info":[{"award-number":["IIT-2025-63"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02172-6","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:33:13Z","timestamp":1785501193000},"page":"1947-1956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative clinical evaluation of endothelin receptor antagonists in pulmonary arterial hypertension using a multi-criteria decision analysis framework"],"prefix":"10.1007","volume":"48","author":[{"given":"Zihan","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"16","key":"2172_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra035488","volume":"351","author":"HW Farber","year":"2004","unstructured":"Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655\u201365. https:\/\/doi.org\/10.1056\/NEJMra035488.","journal-title":"N Engl J Med"},{"issue":"1","key":"2172_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12020","volume":"12","author":"S Emmons-Bell","year":"2022","unstructured":"Emmons-Bell S, Johnson C, Boon-Dooley A, et al. Prevalence, incidence, and survival of pulmonary arterial hypertension: a systematic review for the global burden of disease 2020 study. Pulm Circ. 2022;12(1):e12020. https:\/\/doi.org\/10.1002\/pul2.12020.","journal-title":"Pulm Circ"},{"issue":"2","key":"2172_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","volume":"61","author":"N Gali\u00e9","year":"2004","unstructured":"Gali\u00e9 N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61(2):227\u201337. https:\/\/doi.org\/10.1016\/j.cardiores.2003.11.026.","journal-title":"Cardiovasc Res"},{"issue":"38","key":"2172_CR4","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J"},{"issue":"07","key":"2172_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.19803\/j.1672-8629.2022.07.25","volume":"19","author":"P Yang","year":"2022","unstructured":"Yang P, Lu S, Dong X, et al. Research progress in comprehensive evaluation methods of drugs. Chin J Pharmacovigil. 2022;19(07):803\u20136. https:\/\/doi.org\/10.19803\/j.1672-8629.2022.07.25.","journal-title":"Chin J Pharmacovigil"},{"key":"2172_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2018.00287","volume":"6","author":"A Baran-Kooiker","year":"2018","unstructured":"Baran-Kooiker A, Czech M, Kooiker C. Multi-criteria decision analysis (MCDA) models in health technology assessment of orphan drugs-a systematic literature review. Next steps in methodology development? Front Public Health. 2018;6:287. https:\/\/doi.org\/10.3389\/fpubh.2018.00287.","journal-title":"Front Public Health"},{"issue":"1","key":"2172_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40258-015-0203-4","volume":"14","author":"AC M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher AC, Kaczynski A. Making good decisions in healthcare with multi-criteria decision analysis: the use, current research and future development of MCDA. Appl Health Econ Health Policy. 2016;14(1):29\u201340. https:\/\/doi.org\/10.1007\/s40258-015-0203-4.","journal-title":"Appl Health Econ Health Policy"},{"issue":"8","key":"2172_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68117","volume":"16","author":"A Rasheed","year":"2024","unstructured":"Rasheed A, Aslam S, Sadiq HZ, et al. New and emerging therapeutic drugs for the treatment of pulmonary arterial hypertension: a systematic review. Cureus. 2024;16(8):e68117. https:\/\/doi.org\/10.7759\/cureus.68117.","journal-title":"Cureus"},{"issue":"4","key":"2172_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s41030-023-00244-w","volume":"9","author":"J Omura","year":"2023","unstructured":"Omura J, Makanji Y, Tanabe N, et al. Comparative treatment persistence and adherence to endothelin receptor antagonists among patients with pulmonary arterial hypertension in Japan: a real-world administrative claims database study. Pulm Ther. 2023;9(4):511\u201326. https:\/\/doi.org\/10.1007\/s41030-023-00244-w.","journal-title":"Pulm Ther"},{"issue":"9288","key":"2172_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0140-6736(01)06250-x","volume":"358","author":"RN Channick","year":"2001","unstructured":"Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist Bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119\u201323. https:\/\/doi.org\/10.1016\/s0140-6736(01)06250-x.","journal-title":"Lancet"},{"issue":"1","key":"2172_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/1753465808103499","volume":"3","author":"G Valerio","year":"2009","unstructured":"Valerio G, Bracciale P, Grazia D\u2019Agostino A. Effect of Bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009;3(1):15\u201321. https:\/\/doi.org\/10.1177\/1753465808103499.","journal-title":"Ther Adv Respir Dis"},{"issue":"25","key":"2172_CR12","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","volume":"52","author":"X Ja\u00efs","year":"2008","unstructured":"Ja\u00efs X, D\u2019Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(25):2127\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2008.08.059.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2172_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/circulationaha.106.630715","volume":"114","author":"N Gali\u00e8","year":"2006","unstructured":"Gali\u00e8 N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48\u201354. https:\/\/doi.org\/10.1161\/circulationaha.106.630715.","journal-title":"Circulation"},{"issue":"23","key":"2172_CR14","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/circulationaha.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010\u20139. https:\/\/doi.org\/10.1161\/circulationaha.107.742510.","journal-title":"Circulation"},{"issue":"12","key":"2172_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896\u2013903. https:\/\/doi.org\/10.1056\/NEJMoa012212.","journal-title":"N Engl J Med"},{"issue":"9630","key":"2172_CR16","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/s0140-6736(08)60919-8","volume":"371","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093\u2013100. https:\/\/doi.org\/10.1016\/s0140-6736(08)60919-8.","journal-title":"Lancet"},{"issue":"7","key":"2172_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/s2213-2600(19)30091-8","volume":"7","author":"O Sitbon","year":"2019","unstructured":"Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7(7):594\u2013604. https:\/\/doi.org\/10.1016\/s2213-2600(19)30091-8.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2172_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1981-0","volume":"21","author":"Z Pan","year":"2019","unstructured":"Pan Z, Marra AM, Benjamin N, et al. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Res Ther. 2019;21(1):217. https:\/\/doi.org\/10.1186\/s13075-019-1981-0.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2172_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1213917.","journal-title":"N Engl J Med"},{"issue":"10","key":"2172_CR20","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1136\/ard.2005.048967","volume":"65","author":"CP Denton","year":"2006","unstructured":"Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006;65(10):1336\u201340. https:\/\/doi.org\/10.1136\/ard.2005.048967.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2172_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0011-393X(02)80029-7","volume":"63","author":"DB Badesch","year":"2002","unstructured":"Badesch DB, Bodin F, Channick RN, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Curr Ther Res Clin Exp. 2002;63(4):227\u201346.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"6","key":"2172_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00042737-200406000-00003","volume":"16","author":"K Bambha","year":"2004","unstructured":"Bambha K, Kim WR. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. Eur J Gastroenterol Hepatol. 2004;16(6):519\u201326. https:\/\/doi.org\/10.1097\/00042737-200406000-00003.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"2172_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jval.2017.12.017","volume":"21","author":"SD Pearson","year":"2018","unstructured":"Pearson SD. The ICER value framework: Integrating cost effectiveness and affordability in the assessment of health care value. Value Health. 2018;21(3):258\u201365. https:\/\/doi.org\/10.1016\/j.jval.2017.12.017.","journal-title":"Value Health"},{"issue":"1","key":"2172_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejor.2004.04.028","volume":"169","author":"OS Vaidya","year":"2006","unstructured":"Vaidya OS, Kumar S. Analytic hierarchy process: an overview of applications. Eur J Oper Res. 2006;169(1):1\u201329.","journal-title":"Eur J Oper Res"},{"key":"2172_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-0716-1566-9_3","volume":"2345","author":"S Kanters","year":"2022","unstructured":"Kanters S. Fixed- and random-effects models. Methods Mol Biol. 2022;2345:41\u201365. https:\/\/doi.org\/10.1007\/978-1-0716-1566-9_3.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2172_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.healun.2018.11.006","volume":"38","author":"JL Vachi\u00e9ry","year":"2019","unstructured":"Vachi\u00e9ry JL, Gali\u00e8 N, Barber\u00e1 JA, et al. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension\u2012related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2019;38(2):194\u2013202. https:\/\/doi.org\/10.1016\/j.healun.2018.11.006.","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"2172_CR27","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1007\/s12325-022-02199-x","volume":"39","author":"R Souza","year":"2022","unstructured":"Souza R, Delcroix M, Gali\u00e9 N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39(9):4374\u201390. https:\/\/doi.org\/10.1007\/s12325-022-02199-x.","journal-title":"Adv Ther"},{"issue":"6","key":"2172_CR28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s11096-024-01757-3","volume":"46","author":"J Gu","year":"2024","unstructured":"Gu J, Guo Y, Wu B, et al. Liver injury associated with endothelin receptor antagonists: a pharmacovigilance study based on FDA adverse event reporting system data. Int J Clin Pharm. 2024;46(6):1307\u201316. https:\/\/doi.org\/10.1007\/s11096-024-01757-3.","journal-title":"Int J Clin Pharm"},{"key":"2172_CR29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1017\/s0266462320000525","volume":"36","author":"TL Laba","year":"2020","unstructured":"Laba TL, Jiwani B, Crossland R, et al. Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience. Int J Technol Assess Health Care. 2020;36:434\u20139. https:\/\/doi.org\/10.1017\/s0266462320000525.","journal-title":"Int J Technol Assess Health Care"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02172-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:15Z","timestamp":1789117095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02172-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2172"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02172-6","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was strictly conducted in accordance with the principles of the Declaration of Helsinki and, in compliance with the Chinese \u201cMeasures for Ethical Review of Life Sciences and Medical Research Involving Human Subjects,\u201d obtained an ethics exemption approval from the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (approval date November 12, 2025).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}